HER2 Support Group Forums - View Single Post - Genentech’s T-DM1 Phase III study on HER2-positive mBC meets primary endpoint

annmask · 04-10-2013, 04:59 AM

The problem of crossing bbb continues to be problematic, but Kadcyla is a wonderful new life extender, and QOA improver for us. We are all very grateful to have this option, and angry that it took so long to get here. The cost of these drugs is significantly increased by lengthly trial processes that result in many women dying while waiting for a chance to give a promising, well vetted new drug a try. While Tykerb crosses the bbb, many if not most suffer awful GI problems, and the activity in the brain is very weak- about 19%, explaining why it has been so disappointing as a brain treatment. Clearly we need new. more effective and less toxic small molecule drugs to fight HER2 disease, and many companies are working on this. Kadcyla is by fart the best yet for mets in the body for high expressing HER2+ MBC. May even be curative if given earlier in the disease process, that will be several year down the road as thing are currently going.

04-10-2013, 04:59 AM	#5
annmask Senior Member Join Date: Sep 2010 Location: New hampshire Posts: 44	Re: Genentech’s T-DM1 Phase III study on HER2-positive mBC meets primary endpoint The problem of crossing bbb continues to be problematic, but Kadcyla is a wonderful new life extender, and QOA improver for us. We are all very grateful to have this option, and angry that it took so long to get here. The cost of these drugs is significantly increased by lengthly trial processes that result in many women dying while waiting for a chance to give a promising, well vetted new drug a try. While Tykerb crosses the bbb, many if not most suffer awful GI problems, and the activity in the brain is very weak- about 19%, explaining why it has been so disappointing as a brain treatment. Clearly we need new. more effective and less toxic small molecule drugs to fight HER2 disease, and many companies are working on this. Kadcyla is by fart the best yet for mets in the body for high expressing HER2+ MBC. May even be curative if given earlier in the disease process, that will be several year down the road as thing are currently going.